-
1
-
-
79955005365
-
Minimal residual disease in acute lymphoblastic leukemia
-
Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2010; 2010:7-12.
-
(2010)
Hematol Am Soc Hematol Educ Program
, vol.2010
, pp. 7-12
-
-
Campana, D.1
-
2
-
-
65649143517
-
MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR
-
van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009; 538:115-150.
-
(2009)
Methods Mol Biol
, vol.538
, pp. 115-150
-
-
Van Der Velden, V.H.1
Van Dongen, J.J.2
-
3
-
-
78649506177
-
Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing
-
Coustan-Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol 2010; 23:347-358.
-
(2010)
Best Pract Res Clin Haematol
, vol.23
, pp. 347-358
-
-
Coustan-Smith, E.1
Campana, D.2
-
4
-
-
77949424466
-
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel Germany 18-20 September 2008
-
Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24:521-535.
-
(2010)
Leukemia
, vol.24
, pp. 521-535
-
-
Bruggemann, M.1
Schrauder, A.2
Raff, T.3
-
5
-
-
77954727839
-
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
-
Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115:4657-4663.
-
(2010)
Blood
, vol.115
, pp. 4657-4663
-
-
Stow, P.1
Key, L.2
Chen, X.3
-
6
-
-
77954601328
-
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing
-
Boyd SD, Marshall EL, Merker JD, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1:12ra23.
-
(2009)
Sci Transl Med
, vol.1
-
-
Boyd, S.D.1
Marshall, E.L.2
Merker, J.D.3
-
7
-
-
84873069356
-
Highly sensitive detection of minimal residual disease in acute lymphoblastic leukemia using next-generation sequencing of immunoglobulin heavy chain variable region
-
Faham M, Willis T, Moorhead M, et al. Highly sensitive detection of minimal residual disease in acute lymphoblastic leukemia using next-generation sequencing of immunoglobulin heavy chain variable region. Blood 2011; 118: 1089-1090.
-
(2011)
Blood
, vol.118
, pp. 1089-1090
-
-
Faham, M.1
Willis, T.2
Moorhead, M.3
-
8
-
-
0032770146
-
Detection of minimal residual disease in acute leukemia by flow cytometry
-
DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H
-
Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38:139-152. (Pubitemid 29390417)
-
(1999)
Communications in Clinical Cytometry
, vol.38
, Issue.4
, pp. 139-152
-
-
Campana, D.1
Coustan-Smith, E.2
-
9
-
-
17944380938
-
BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings
-
DOI 10.1038/sj.leu.2402150
-
Lucio P, Gaipa G, van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001; 15:1185-1192. (Pubitemid 32776442)
-
(2001)
Leukemia
, vol.15
, Issue.8
, pp. 1185-1192
-
-
Lucio, P.1
Gaipa, G.2
Van Lochem, E.G.3
Van Wering, E.R.4
Porwit-MacDonald, A.5
Faria, T.6
Bjorklund, E.7
Biondi, A.8
Van Den Beemd, M.W.M.9
Baars, E.10
Vidriales, B.11
Parreira, A.12
Van Dongen, J.J.M.13
San Miguel, J.F.14
Orfao, A.15
-
10
-
-
66249133415
-
Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection
-
DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 2009; 76:150-155.
-
(2009)
Cytometry B Clin Cytom
, vol.76
, pp. 150-155
-
-
Digiuseppe, J.A.1
Fuller, S.G.2
Borowitz, M.J.3
-
11
-
-
0035313156
-
Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
-
DOI 10.1182/blood.V97.7.2115
-
Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97:2115-2120. (Pubitemid 32239094)
-
(2001)
Blood
, vol.97
, Issue.7
, pp. 2115-2120
-
-
Chen, J.-S.1
Coustan-Smith, E.2
Suzuki, T.3
Neale, G.A.4
Mihara, K.5
Pui, C.-H.6
Campana, D.7
-
12
-
-
79959450187
-
New markers for minimal residual disease detection in acute lymphoblastic leukemia
-
Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117:6267-6276.
-
(2011)
Blood
, vol.117
, pp. 6267-6276
-
-
Coustan-Smith, E.1
Song, G.2
Clark, C.3
-
13
-
-
83855162770
-
CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry
-
Solly F, Angelot F, Garand R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A 2012; 81:17-24.
-
(2012)
Cytometry A
, vol.81
, pp. 17-24
-
-
Solly, F.1
Angelot, F.2
Garand, R.3
-
14
-
-
67650718769
-
Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
-
Djokic M, Bjorklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica 2009; 94:1016-1019.
-
(2009)
Haematologica
, vol.94
, pp. 1016-1019
-
-
Djokic, M.1
Bjorklund, E.2
Blennow, E.3
-
15
-
-
70449721037
-
Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: Utility in detection of minimal residual disease by flow cytometry
-
Muzzafar T, Medeiros LJ, Wang SA, et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009; 132:692-698.
-
(2009)
Am J Clin Pathol
, vol.132
, pp. 692-698
-
-
Muzzafar, T.1
Medeiros, L.J.2
Wang, S.A.3
-
16
-
-
77952570617
-
CD11b is a therapy resistance and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia
-
Rhein P, Mitlohner R, Basso G, et al. CD11b is a therapy resistance and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood 2010; 115:3763-3771.
-
(2010)
Blood
, vol.115
, pp. 3763-3771
-
-
Rhein, P.1
Mitlohner, R.2
Basso, G.3
-
17
-
-
56749104572
-
A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders
-
Pedreira CE, Costa ES, Almeida J, et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008; 73A:1141-1150.
-
(2008)
Cytometry A
, vol.73 A
, pp. 1141-1150
-
-
Pedreira, C.E.1
Costa, E.S.2
Almeida, J.3
-
18
-
-
83855162815
-
Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data
-
Fiser K, Sieger T, Schumich A, et al. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry A 2012; 81:25-34.
-
(2012)
Cytometry A
, vol.81
, pp. 25-34
-
-
Fiser, K.1
Sieger, T.2
Schumich, A.3
-
19
-
-
19944428207
-
Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection
-
DOI 10.1038/sj.leu.2403559
-
Gaipa G, Basso G, Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19:49-56. (Pubitemid 40090076)
-
(2005)
Leukemia
, vol.19
, Issue.1
, pp. 49-56
-
-
Gaipa, G.1
Basso, G.2
Maglia, O.3
Leoni, V.4
Faini, A.5
Cazzaniga, G.6
Bugarin, C.7
Veltroni, M.8
Michelotto, B.9
Ratei, R.10
Coliva, T.11
Valsecchi, M.G.12
Biondi, A.13
Dworzak, M.N.14
-
20
-
-
77952630014
-
Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon
-
Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group
-
Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78:147-153.
-
(2010)
Cytometry B Clin Cytom
, vol.78
, pp. 147-153
-
-
Dworzak, M.N.1
Gaipa, G.2
Schumich, A.3
-
21
-
-
84856229635
-
A new method for high speed, sensitive detection of minimal residual disease
-
Liu X, Hsieh HB, Campana D, Bruce RH. A new method for high speed, sensitive detection of minimal residual disease. Cytometry A 2012; 81:169-175.
-
(2012)
Cytometry A
, vol.81
, pp. 169-175
-
-
Liu, X.1
Hsieh, H.B.2
Campana, D.3
Bruce, R.H.4
-
22
-
-
47049093795
-
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study
-
Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. a Children's Oncology Group study. Blood 2008; 111:5477-5485.
-
(2008)
Blood
, vol.111
, pp. 5477-5485
-
-
Borowitz, M.J.1
Devidas, M.2
Hunger, S.P.3
-
23
-
-
70449711125
-
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow
-
Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27:5168-5174.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5168-5174
-
-
Basso, G.1
Veltroni, M.2
Valsecchi, M.G.3
-
24
-
-
67649410242
-
Treating childhood acute lymphoblastic leukemia without cranial irradiation
-
Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360:2730-2741.
-
(2009)
N Engl J Med
, vol.360
, pp. 2730-2741
-
-
Pui, C.H.1
Campana, D.2
Pei, D.3
-
25
-
-
66749117163
-
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multicenter setting
-
Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multicenter setting. Haematologica 2009; 94:870-874.
-
(2009)
Haematologica
, vol.94
, pp. 870-874
-
-
Irving, J.1
Jesson, J.2
Virgo, P.3
-
26
-
-
78349293365
-
Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia
-
Luria D, Rosenthal E, Steinberg D, et al. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry B Clin Cytom 2010; 78:365-371.
-
(2010)
Cytometry B Clin Cytom
, vol.78
, pp. 365-371
-
-
Luria, D.1
Rosenthal, E.2
Steinberg, D.3
-
27
-
-
73349090614
-
Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry
-
Mejstrikova E, Fronkova E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010; 54:62-70.
-
(2010)
Pediatr Blood Cancer
, vol.54
, pp. 62-70
-
-
Mejstrikova, E.1
Fronkova, E.2
Kalina, T.3
-
28
-
-
0027976273
-
Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
-
Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196-200.
-
(1994)
Lancet
, vol.343
, pp. 196-200
-
-
Brisco, M.J.1
Condon, J.2
Hughes, E.3
-
29
-
-
0032572924
-
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
-
DOI 10.1056/NEJM199808273390904
-
Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer: Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591-598. (Pubitemid 28385656)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.9
, pp. 591-598
-
-
Cave, H.1
Van Der Werff Ten Bosch, J.2
Suciu, S.3
Guidal, C.4
Waterkeyn, C.5
Otten, J.6
Bakkus, M.7
Thielemans, K.8
Grandchamp, B.9
Vilmer, E.10
Nelken, B.11
Fournier, M.12
Boutard, P.13
Lebrun, E.14
Mechinaud, F.15
Garand, R.16
Robert, A.17
Dastugue, N.18
Plouvier, E.19
Racador, E.20
Ferster, A.21
Gyselinck, J.22
Fenneteau, O.23
Duval, M.24
Solbu, G.25
Manel, A.-M.26
more..
-
30
-
-
0347184138
-
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
-
DOI 10.1016/S0140-6736(97)10295-1
-
Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550-554. (Pubitemid 28077560)
-
(1998)
Lancet
, vol.351
, Issue.9102
, pp. 550-554
-
-
Coustan-Smith, E.1
Behm, F.G.2
Sanchez, J.3
Boyett, J.M.4
Hancock, M.L.5
Raimondi, S.C.6
Rubnitz, J.E.7
Rivera, G.K.8
Sandlund, J.T.9
Pui, C.-H.10
Campana, D.11
-
31
-
-
0032576355
-
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
-
van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731-1738. (Pubitemid 28534955)
-
(1998)
Lancet
, vol.352
, Issue.9142
, pp. 1731-1738
-
-
Van Dongen, J.J.M.1
Seriu, T.2
Panzer-Grumayer, E.R.3
Biondi, A.4
Pongers-Willemse, M.J.5
Corral, L.6
Stolz, F.7
Schrappe, M.8
Masera, G.9
Kamps, W.A.10
Gadner, H.11
Van Wering, E.R.12
Ludwig, W.-D.13
Basso, G.14
De Bruijn, M.A.C.15
Cazzaniga, G.16
Hettinger, K.17
Van Der Does-Van Den Berg, A.18
Hop, W.C.J.19
Riehm, H.20
Bartram, C.R.21
more..
-
32
-
-
0034667685
-
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
-
Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691-2696.
-
(2000)
Blood
, vol.96
, pp. 2691-2696
-
-
Coustan-Smith, E.1
Sancho, J.2
Hancock, M.L.3
-
33
-
-
0036660158
-
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
-
DOI 10.1182/blood-2002-01-0006
-
Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100:52-58. (Pubitemid 35177428)
-
(2002)
Blood
, vol.100
, Issue.1
, pp. 52-58
-
-
Coustan-Smith, E.1
Sancho, J.2
Behm, F.G.3
Hancock, M.L.4
Razzouk, B.I.5
Ribeiro, R.C.6
Rivera, G.K.7
Rubnitz, J.E.8
Sandlund, J.T.9
Pui, C.-H.10
Campana, D.11
-
34
-
-
0037085750
-
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia
-
DOI 10.1182/blood.V99.6.1952
-
DworzakMN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99:1952-1958. (Pubitemid 34525474)
-
(2002)
Blood
, vol.99
, Issue.6
, pp. 1952-1958
-
-
Dworzak, M.N.1
Froschl, G.2
Printz, D.3
Mann, G.4
Potschger, U.5
Muhlegger, N.6
Fritsch, G.7
Gadner, H.8
-
35
-
-
34548817262
-
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
-
DOI 10.1182/blood-2006-09-045369
-
Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007; 110: 1607-1611. (Pubitemid 47443978)
-
(2007)
Blood
, vol.110
, Issue.5
, pp. 1607-1611
-
-
Zhou, J.1
Goldwasser, M.A.2
Li, A.3
Dahlberg, S.E.4
Neuberg, D.5
Wang, H.6
Dalton, V.7
McBride, K.D.8
Sallan, S.E.9
Silverman, L.B.10
Gribben, J.G.11
-
36
-
-
67650478894
-
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
-
Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009; 146:292-299.
-
(2009)
Br J Haematol
, vol.146
, pp. 292-299
-
-
Sutton, R.1
Venn, N.C.2
Tolisano, J.3
-
37
-
-
77951441599
-
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study
-
Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.
-
(2010)
Blood
, vol.115
, pp. 3206-3214
-
-
Conter, V.1
Bartram, C.R.2
Valsecchi, M.G.3
-
38
-
-
78049300632
-
Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group
-
Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010; 55:1287-1295.
-
(2010)
Pediatr Blood Cancer
, vol.55
, pp. 1287-1295
-
-
Yamaji, K.1
Okamoto, T.2
Yokota, S.3
-
39
-
-
77951787638
-
Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit
-
Katsibardi K, Moschovi MA, Braoudaki M, et al. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit. Leuk Lymphoma 2010; 51:846-852.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 846-852
-
-
Katsibardi, K.1
Moschovi, M.A.2
Braoudaki, M.3
-
40
-
-
80052079740
-
Prognostic value of MRDdynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols
-
Meleshko AN, Savva NN, Fedasenka UU, et al. Prognostic value of MRDdynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res 2011; 35:1312-1320.
-
(2011)
Leuk Res
, vol.35
, pp. 1312-1320
-
-
Meleshko, A.N.1
Savva, N.N.2
Fedasenka, U.U.3
-
41
-
-
0035856232
-
Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia
-
DOI 10.1016/S0140-6736(01)06355-3
-
Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358:1239-1241. (Pubitemid 33010852)
-
(2001)
Lancet
, vol.358
, Issue.9289
, pp. 1239-1241
-
-
Eckert, C.1
Biondi, A.2
Seeger, K.3
Cazzaniga, G.4
Hartmann, R.5
Beyermann, B.6
Pogodda, M.7
Proba, J.8
Henze, G.9
-
42
-
-
1542503795
-
Clinical significant of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
-
DOI 10.1038/sj.leu.2403283
-
Coustan-Smith E, Gajjar A, Hijiha N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004; 18:499-504. (Pubitemid 38425864)
-
(2004)
Leukemia
, vol.18
, Issue.3
, pp. 499-504
-
-
Coustan-Smith, E.1
Gajjar, A.2
Hijiya, N.3
Razzouk, B.I.4
Ribeiro, R.C.5
Rivera, G.K.6
Rubnitz, J.E.7
Sandlund, J.T.8
Andreansky, M.9
Hancock, M.L.10
Pui, C.-H.11
Campana, D.12
-
43
-
-
57849085208
-
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia
-
Paganin M, Zecca M, Fabbri G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008; 22:2193-2200.
-
(2008)
Leukemia
, vol.22
, pp. 2193-2200
-
-
Paganin, M.1
Zecca, M.2
Fabbri, G.3
-
44
-
-
50549083190
-
Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma
-
Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol 2008; 26:3971-3978.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3971-3978
-
-
Raetz, E.A.1
Borowitz, M.J.2
Devidas, M.3
-
45
-
-
11144355701
-
Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: A report of the Pre-BMT MRD Study Group
-
DOI 10.1038/sj.bmt.1704241
-
Krejci O, van der Velden V, Bader P, et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32:849-851. (Pubitemid 38455954)
-
(2003)
Bone Marrow Transplantation
, vol.32
, Issue.8
, pp. 849-851
-
-
Krejci, O.1
Van Der Velden, V.H.J.2
Bader, P.3
Kreyenberg, H.4
Goulden, N.5
Hancock, J.6
Schilham, M.W.7
Lankester, A.8
Revesz, T.9
Klingebiel, T.10
Van Dongen, J.J.M.11
-
46
-
-
58549091682
-
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group
-
Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27:377-384.
-
(2009)
J Clin Oncol
, vol.27
, pp. 377-384
-
-
Bader, P.1
Kreyenberg, H.2
Henze, G.H.3
-
47
-
-
79960495326
-
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia
-
Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118:223-230.
-
(2011)
Blood
, vol.118
, pp. 223-230
-
-
Leung, W.1
Campana, D.2
Yang, J.3
-
48
-
-
84857365039
-
Monitoring MRD with flow cytometry: An effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation
-
Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012; 91:183-192.
-
(2012)
Ann Hematol
, vol.91
, pp. 183-192
-
-
Zhao, X.S.1
Liu, Y.R.2
Zhu, H.H.3
-
49
-
-
80052172961
-
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study
-
Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118:2077-2084.
-
(2011)
Blood
, vol.118
, pp. 2077-2084
-
-
Schrappe, M.1
Valsecchi, M.G.2
Bartram, C.R.3
-
50
-
-
67349225042
-
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
-
van der Velden V, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23:1073-1079.
-
(2009)
Leukemia
, vol.23
, pp. 1073-1079
-
-
Van Der Velden, V.1
Corral, L.2
Valsecchi, M.G.3
-
51
-
-
79961191931
-
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906
-
Bowman WP, Larsen EL, Devidas M, et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer 2011; 57:569-577.
-
(2011)
Pediatr Blood Cancer
, vol.57
, pp. 569-577
-
-
Bowman, W.P.1
Larsen, E.L.2
Devidas, M.3
-
52
-
-
33745622137
-
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
-
DOI 10.1182/blood-2006-01-0066
-
Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006; 108:97-102. (Pubitemid 43990616)
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 97-102
-
-
Coustan-Smith, E.1
Ribeiro, R.C.2
Stow, P.3
Zhou, Y.4
Pui, C.-H.5
Rivera, G.K.6
Pedrosa, F.7
Campana, D.8
-
53
-
-
79951804790
-
Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia
-
Koh KN, Park M, Kim BE, et al. Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia. Korean J Pediatr 2010; 53:957-964.
-
(2010)
Korean J Pediatr
, vol.53
, pp. 957-964
-
-
Koh, K.N.1
Park, M.2
Kim, B.E.3
-
54
-
-
77955714137
-
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
-
Lankester AC, Bierings MB, Van Wering ER, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010; 24:1462-1469.
-
(2010)
Leukemia
, vol.24
, pp. 1462-1469
-
-
Lankester, A.C.1
Bierings, M.B.2
Van Wering, E.R.3
-
55
-
-
58749109707
-
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
-
Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470-480.
-
(2009)
N Engl J Med
, vol.360
, pp. 470-480
-
-
Mullighan, C.G.1
Su, X.2
Zhang, J.3
-
56
-
-
58749095816
-
Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia
-
Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147-156.
-
(2009)
Lancet Oncol
, vol.10
, pp. 147-156
-
-
Coustan-Smith, E.1
Mullighan, C.G.2
Onciu, M.3
-
57
-
-
84862127741
-
Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia
-
doi:10.1002/pbc.23395 [Epub ahead of print]
-
Rabin KR, Gramatges MM, Borowitz MJ, et al. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011. doi:10.1002/pbc.23395. [Epub ahead of print]
-
(2011)
Pediatr Blood Cancer
-
-
Rabin, K.R.1
Gramatges, M.M.2
Borowitz, M.J.3
-
58
-
-
79952362834
-
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia
-
Lonnerholm G, Thorn I, Sundstrom C, et al. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia. Leuk Res 2011; 35:472-478.
-
Leuk Res 2011
, vol.35
, pp. 472-478
-
-
Lonnerholm, G.1
Thorn, I.2
Sundstrom, C.3
-
59
-
-
79751538993
-
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
-
Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25:254-258.
-
(2011)
Leukemia
, vol.25
, pp. 254-258
-
-
Waanders, E.1
Van Der Velden, V.H.2
Van Der Schoot, C.E.3
-
60
-
-
79959312575
-
Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
-
Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-2498.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2493-2498
-
-
Topp, M.S.1
Kufer, P.2
Gokbuget, N.3
|